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Langerhans cell histiocytosis (LCH) is a disease that can involve one or multiple organ 
systems characterized by an accumulation of CD1a
 
 
 
 Langerhans-like cells as well as several 
other myeloid cell types. The precise origin and role of one of these populations, the 
multinucleated giant cell (MGC), in this disease remains unknown. This work shows that in 
three different lesional tissues, bone, skin, and lymph node, the MGCs expressed the 
characteristic osteoclast markers, tartrate-resistant acid phosphatase and vitronectin 
receptor, as well as the enzymes cathepsin K and matrix metalloproteinase-9. Although, in 
bone lesions, the osteoclast-like MGCs were only CD68
 
 
 
, in the nonostotic sites, they 
coexpressed CD1a. The presence of osteoclast-like MGCs may be explained by the 
production of osteoclast-inducing cytokines such as receptor activator of nuclear factor 
 
 
 
B 
ligand and macrophage colony-stimulating factor by both the CD1a
 
 
 
 LCH cells and T cells in 
these lesions. As osteoclast-derived enzymes play a major role in tissue destruction, the 
osteoclast-like nature of MGCs in all LCH lesions makes them a potential target for the 
treatment of this disease.
 
Langerhans cell (LC) histiocytosis (LCH) is a rare
disease often present in childhood with a
continuum of clinical entities ranging from a
localized lytic lesion to a fatal disseminated
myeloid-like leukemia and is associated with
fibrosis and osteolysis, which leads to organ
dysfunction (1). Although the pathophysiology
is still obscure, at the cellular level, LCH is
characterized by the clonal proliferation and
retention of CD1a
 
 
 
 dendritic LCs, commonly
referred to as LCH cells. Together with LCH
cells, other cell types have been shown to be
present in LCH lesions, including lympho-
cytes, macrophages, eosinophils, and multinu-
cleated giant cells (MGCs; reference 2).
MGCs are thought to originate from the
fusion of monocyte–macrophage lineage cells
(3). Morphologically, they can be classified
into Langhans giant cells (normally found in
infective granulomatous diseases; reference 4),
foreign body giant cells (commonly found in
foreign body granulomas; reference 5), or
thirdly, osteoclasts, which are present in bone
sites where they function in bone resorption
(6). Although all these types of MGCs origi-
nate from a common precursor cell, they differ
markedly in their association with disease
states, location, and prevalence in various tissues
or organs, stimuli that induce their formation,
and subsequent function.
It is unclear how monocyte fusion is in-
duced in vivo and whether different mecha-
nisms are involved in different pathological
states. However, a number of papers have re-
ported on how the formation of MGCs can be
induced in vitro. Evidence has accumulated to
show that the in vitro generation of MGCs oc-
curs as a result of cell fusion rather than cell di-
vision (7). In fact, the in vitro fusion of ad-
herent macrophages from both humans and
experimental animals is a normal event at a
terminal stage of maturation (8). This phenom-
enon is enhanced, among other stimuli, by the
addition of various cytokines. Indeed, the
cytokines IL-4, IFN-
 
 
 
, or IL-13 clearly play a
prominent role in monocyte fusion and, subse-
quently, in the generation of MGCs (5, 9).
Furthermore, an appropriate cytokine environ-
ment can regulate the commitment of a cell to-
ward one or another cell lineage. For example,
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osteoclast differentiation from monocyte–macrophage pre-
cursor cells occurs in the presence of cytokines, such as
TNF-
 
 
 
 and IL-1
 
  
 
(10) or receptor activator of NF-
 
 
 
B ligand
(RANKL), and growth factors, such as M-CSF (11). In con-
trast, although DCs originate from the same monocyte–mac-
rophage precursor cells as osteoclasts, DCs are derived in
vitro from circulating human monocytes after stimulation
with GM-CSF, IFN-
 
 
 
, and IL-4 (12, 13), or from human
CD34
 
 
 
 myeloid progenitors in response to GM-CSF and
TNF-
 
 
 
 
 
(14). These bone marrow progenitors were identified
recently through their ability to differentiate into DCs or os-
teoclasts, depending on whether RANKL was present to-
gether with GM-CSF or M-CSF, respectively (15).
Thus, it is clear that the cellular environment plays a cru-
cial role in cell differentiation. In this report, we demonstrate
that the cytokine environment of LCH lesions may allow lo-
cal formation rather than attraction of osteoclast-like MGCs.
The local formation may explain the coexpression of CD1a
observed on osteoclast-like MGCs in nonbone lesions as the
normal osteoclast precursors are likely to be absent in these
tissues. So, although the phenotype of the osteoclast-like
MGCs was more normal in bone lesions, it seems likely that
this population must contribute a large part of the chronic
tissue destruction in all LCH lesions. Thus, the osteoclast-
like nature of MGCs provides a rationale for the successful
treatment of LCH patients with antiosteoclast therapy.
Figure 1. Phenotypic characterization of MGCs in LCH lesions for 
osteoclast markers. (A) MGCs in bone (left) and skin (right) LCH lesions 
were TRAP . (B) Triple-color immunofluorescent staining for CD68, CatK, 
and VNR in an LCH bone lesion (left) and a skin lesion (right). (C) Double im-
munofluorescent staining for CD68 and another osteoclast marker, MMP-9, 
in an LCH bone lesion. Original magnifications, (A) 220; (B) 290; and (C) 270. 
JEM VOL. 201, March 7, 2005
 
689
 
BRIEF DEFINITIVE REPORT
 
RESULTS AND DISCUSSION
MGCs in LCH lesions phenotypically express 
osteoclast markers
 
Although the different types of MGCs all have a hematopoi-
etic precursor, the osteoclast has very distinct functional and
phenotypic characteristics (3). Thus, to clarify whether the
MGCs observed in LCH lesions are indeed of an osteoclast-
like phenotype, we performed multicolor immunohis-
tochemical analysis for the typical osteoclast markers, CD68,
tartrate-resistant acid phosphatase (TRAP), vitronectin re-
ceptor (VNR), and the enzymes cathepsin K (CatK) and
matrix metalloproteinase–9 (MMP-9; Table I and Fig. 1).
CD68, a marker of the monocyte–macrophage lineage cells,
was used to detect MGCs in LCH lesions. CD68
 
 
 
 MGCs
were observed in 13 out of the 15 LCH bone biopsies ana-
lyzed. Importantly, MGCs were also found in nonostotic
LCH lesional sites, namely the lymph node (4/4) and the
skin (3/7). Five out of seven nonostotic lesions that con-
tained MGCs stained positive for TRAP (Fig. 1 A, right), an
enzyme present in osteoclastic vesicles that fuse with en-
docytic vesicles containing the bone matrix degradation
products. This enzyme induces the release of reactive oxy-
gen species that destroy the matrix components of the bone
(16). 9 out of the 13 bone lesions also showed TRAP posi-
tivity on the CD68
 
 
 
 MGCs (Fig. 1 A, left). Triple immuno-
fluorescent staining for CD68, VNR, and CatK showed that
all the bone (Fig. 1 B, left) and lymph node lesions (not de-
picted) with MGCs were VNR
 
 
 
 and CatK
 
 
 
. In contrast,
one out of three skin lesions containing MGCs was positive
for VNR and CatK (Fig. 1 B, right). A further enzyme char-
acteristic of osteoclasts, MMP-9, was also present on the
CD68
 
 
 
 MGCs in all bone lesions (Fig. 1 C). Moreover,
MMP-9 was also expressed in the MGCs of skin (1/3) and
lymph node lesions (4/4). CatK and MMP-9 are proteases
 
Table I.
 
Characterization of MGCs in LCH lesions for osteoclast markers, osteoclast-secreted enzymes, and osteoclast-inducing environment
 
MGCs in lesion Lesional environment
Phenotypic markers of osteoclasts Osteoclast-secreting enzymes Osteoclast-inducing cytokines and receptor
Lesional site CD1a CD68 TRAP VNR CatK MMP-9 M-CSF RANKL RANK
 
Bone
 
b1 –
 
              
 
## #
b2 –
 
  
 
–
 
        
 
–# #
b3 – – – – – – # # #
b4 –
 
 
 
–
 
    
 
## #
b5 –
 
             
 
–# #
b6 –
 
                
 
## #
b7 –
 
              
 
#– #
b8 – – – – – – # # #
b9 –
 
  
 
–
 
      
 
#– #
b10 –
 
            
 
#– #
b11 –
 
       
 
## #
b12 –
 
                   
 
#– #
b13 –
 
  
 
–
 
      
 
–# #
b14 –
 
                
 
## #
b15 –
 
           
 
–# #
 
Skin
 
s1
 
                
 
## #
s2 – – – – – – # – #
s3 – – – – – – ND – #
s4 – – – – – – ND ND –
s5 –
 
  
 
–– – N D N DN D
s6 –
 
 
 
–– – – – # #
s7 – – – – – – – – –
 
Lymph node
 
l1
 
                 
 
## N D
l2 ND
 
       
 
## #
l3 –
 
   
 
–
 
           
 
## #
l4
 
          
 
–# #
 
–, absence of expression; 
 
#
 
, expression; 
 
 
 
, 0–30% expression by the MGCs; 
 
  
 
, 30–70% expression by the MGCs; 
 
   
 
, 70–100% expression by the MGCs; ND, not determined 
due to lack of tissue. 
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involved in the degradation of organic components from the
bone matrix, such as type I collagen and other matrix pro-
teins (17, 18). VNR is a receptor for the integrin vitronectin
commonly found in osteoclasts and likely to be involved in
the interaction between the osteoclast and the bone matrix
(19). Thus, the expression of typical osteoclast markers as
well as characteristic osteoclast-secreted enzymes by the
MGCs in LCH lesions confirms that these cells are indeed
osteoclast-like MGCs.
 
Possible origin of MGCs in LCH lesions
 
The presence of these osteoclast-like giant cells in LCH
bone lesions is perhaps not that unusual as this is the normal
tissue site for osteoclasts, which, through their resorbing ac-
tivity, help to maintain the normal homeostasis of the bone
(6). However, even in the ostotic LCH lesions, these osteo-
clast-like cells were present in relatively higher numbers
than in normal bone and appeared to be “floating” within
the cellular infiltrate of the lesion, whereas normally close
contact with bone would be expected. In contrast, the find-
ing of osteoclast-like cells in nonostotic LCH sites raises the
question of their origin. To investigate this, we performed
triple immunofluorescent stainings for the LC marker,
CD1a, the macrophage marker, CD68, and CatK to more
clearly identify the MGCs. In all bone lesions, the CatK
 
 
 
osteoclast-like cells coexpressed the macrophage marker
CD68. In none of the ostotic lesions did these osteoclast-
like MGCs express CD1a (Table I and Fig. 2 A). This find-
ing suggests that the MGCs in bone LCH display the fea-
tures of a normal osteoclast. In contrast, in one out of three
skin and two out of four lymph node lesions that contained
osteoclast-like cells, the MGCs expressed both CD68 and
CD1a (Table I and Fig. 2 B). Hence, although both the os-
teoclast-like giant cells in bone as well as in nonbone lesions
expressed CD68, only the giant cells in skin and lymph node
coexpressed CD1a. This unusual phenotype of these osteo-
clast-like giant cells in skin LCH has been reported before in
a single case without any further characterization (20). The
majority of nonostotic lesions studied were in fact from pa-
tients without additional bone lesions. This excludes the
possibility that the MGCs were derived from bone lesions.
Therefore, it is likely that the lesional environment induces
the local formation of the osteoclast-like MGCs even in un-
usual sites, such as these nonostotic LCH sites. This, to-
gether with the fact that the normal precursors of osteoclasts
are likely to be absent from these sites, may result in osteo-
clast-like MGCs derived from a different origin (e.g.,
CD1a
 
 
 
 cells). Alternatively, the CD1a
 
 
 
 expression by
MGCs in these sites may be due to induced expression of
CD1a at a later stage.
To better understand the likely mechanisms of MGC
formation in LCH lesions, we looked at the expression of
intercellular adhesion molecule-1 (ICAM-1), an adhesion
molecule expressed by monocytes upon fusion to form
MGCs (21) and Ki-67, a nuclear protein associated with so-
matic cell proliferation (22). We found that in all LCH le-
sions, the MGCs displayed strong membrane staining for
ICAM-1. In contrast, the MGCs were consistently negative
for the proliferative marker Ki67 (unpublished data). How-
ever, there was a high expression of Ki-67 in other cells in
the lesions that we and others have shown previously to be
largely due to the CD1a
 
 
 
 LCH cells (23, 24). These findings
suggest that the osteoclast-like MGCs present in LCH le-
sions may be formed by the fusion of resident monocytes–
macrophages rather than by cell division. Cytokines such as
IFN-
 
 
 
, which has previously been shown to be expressed in
LCH lesions (25), are well-known inducers of ICAM-1 ex-
pression and, thus, may initiate the fusion of monocytes and
macrophages to form MGCs. Thus, MGCs seem to be in-
trinsic to LCH lesions and specific factors within the well-
Figure 2. Phenotypic difference in osteoclast-like MGCs in bone 
versus nonbone lesions. Triple immunofluorescent staining for the 
monocyte lineage marker, CD68, DC marker, CD1a, and the enzyme CatK 
was performed in LCH bone (A) and skin (B). The osteoclasts in LCH skin le-
sions clearly expressed CD1a as well as CD68 and CatK (B). In contrast, LCH 
bone lesions never expressed CD1a (A). Original magnification, 260. 
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characterized “cytokine storm” in LCH lesions are responsi-
ble for their formation.
 
The osteoclast-inducing cytokines RANKL and M-CSF are 
highly expressed in LCH lesions
 
As shown by in vitro studies, the environment in which the
mononuclear cells are present determines their differentia-
tion into the various mononuclear phagocyte system-derived
cells. Similarly, the tissue site and environment may have a
large influence on the cellular composition of LCH lesions.
Previous work by our group and others has clearly shown
the presence of a cytokine storm in LCH lesions (25). For
instance, factors involved in osteoclastogenesis such as IL-1,
IL-6, and TNF
 
 
 
 are highly expressed. In the present report,
we have extended the analysis of cytokines to those specifi-
cally involved in the induction of osteoclast differentiation.
One such cytokine involved in osteoclast induction is
RANKL. In 24 LCH lesions studied for RANKL expres-
sion, 17 were found to be positive. We found that this cy-
tokine was not expressed by the endothelial cells and mac-
rophages, as assessed by triple staining combining RANKL
with the CD31 and CD68 markers, respectively (unpub-
lished data). Instead, triple staining for RANKL, CD1a to
identify the LCH cells and the T cell marker CD3, revealed
that the majority of CD1a
 
 
 
 LCH cells and T cells in close
proximity to the LCH cells expressed RANKL (Fig. 3 A).
Thus, both the CD1a
 
 
 
 LCH cells and T cells contribute to
osteoclastogenesis through up-regulated RANKL and, thus,
provide a mechanism for the potentiation of osteoclast for-
mation and bone resorption in LCH lesions.
One key feature of osteoclast differentiation is the inter-
action between RANKL and its receptor, RANK, com-
monly expressed by the osteoclast precursor cells. We
looked at the presence of RANK receptor on CD68
 
 
 
 and
CD1a
 
 
 
 cells by triple immunofluorescent staining. All the
lesions that showed expression of RANKL were also posi-
tive for RANK, which was expressed by a high proportion
of CD1a
 
 
 
 cells and to a lesser extent by CD68 cells as shown
in Fig. 3 B. The expression of RANK by CD1a
 
 
 
 cells as
well as the presence of its ligand by activated T cells in LCH
lesions is also important, as this interaction is known to in-
duce a survival signal to DCs (26).
Furthermore, we looked at the expression of another cy-
tokine known to be involved in osteoclast differentiation,
M-CSF. M-CSF is normally produced by osteoblasts and/or
stromal cells and is involved in the differentiation of osteo-
clasts from an early stage. We found it to be expressed by the
MGCs and strikingly also by CD1a cells in 11 out of 15
LCH bone lesions. Interestingly, we found that this cytokine
 
Figure 3. Expression of cytokines known to be involved in osteo-
clast differentiation in bone and skin LCH.
 
 Two- and three-color im-
munofluorescent stainings were performed for the cytokines RANKL and 
its receptor RANK and M-CSF. (A) Representative picture of an LCH bone 
lesion showing that the majority of the CD1a
 
 
 
 LCH cells (blue) express 
RANKL (green). This colocalization results in a turquoise color. In addition, 
many of the neighboring T cells (red) also expressed RANKL (green). This 
colocalization resulted in a yellow color. (B) The CD1a
 
 
 
 LCH cells (red) also 
expressed RANKR (green). This colocalization results in a yellow color in 
the merged image. (C) Representative picture of an LCH skin lesion show-
ing that the osteoclast differentiation cytokine, M-CSF (green), was ex-
pressed by the CD1a
 
 
 
 LCH cells (red). This colocalization resulted in a yel-
low color in the merged image. In contrast, normal LCs (indicated by 
arrows) in the epidermis (E) did not express any M-CSF. Original magnifi-
cation, (A, B, and C) 270. 
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was even expressed by the CD1a
 
 
 
 cells in 1/3 skin (Fig. 3 C)
and 3/4 lymph node lesions that contained MGCs. The ex-
pression of M-CSF by the lesional CD1a
 
 
 
 cells seemed par-
ticularly relevant as there was clearly no expression of this
cytokine by the normal LCs in both LCH skin lesions (Fig. 3
C) and normal skin (not depicted). The presence of cyto-
kines involved in osteoclast differentiation in LCH lesions
provides an explanation for the presence of osteoclast-like
cells in ostotic as well as nonostotic sites in LCH. An attrac-
tive hypothesis would be that excessive amounts of osteo-
clast-inducing cytokines, such as RANKL and M-CSF,
induce osteoclast-like differentiation of inappropriate pre-
cursors (e.g., CD1a
 
 
 
 LCH cells). Strong support for this
hypothesis was demonstrated in a very recent paper by Ri-
vollier et al. (27). Using human monocyte-derived DCs gen-
erated in vitro, they showed that immature DCs can trans-
differentiate into functional osteoclasts in the presence of
M-CSF and RANKL. Furthermore, they showed that the
proinflammatory cytokines, TNF
 
 
 
 and IL-1
 
 
 
, both of
which are highly expressed in LCH lesions (25), promote
cell fusion during DC transdifferentiation and lead to larger
MGCs than M-CSF plus RANKL alone. Thus, the in vitro
differentiation plasticity seen in cells of the mononu-
clear phagocyte system also appears to occur in vivo in LCH
lesions.
 
Rationale for the use of bisphosphonates in 
the treatment of LCH
 
Due to the lack of fresh biopsy material, it was not possible
to perform functional studies such as the use of dentine discs
to determine the resorbing capacity of the MGCs in LCH
lesions. However, the finding that the MGCs in LCH le-
sions are expressing various matrix-degrading enzymes sup-
ports the hypothesis of a destructive role for these cells in
LCH lesions. Such a role would also help to explain the pre-
dominant symptom of bone pain suffered by patients with
LCH bone lesions. The present report has provided support
for the hypothesis that the excessive bony destruction found
in LCH is likely mediated by osteoclast-like giant cells.
Therefore, these cells are a potential target in LCH lesions.
To date, only a few case reports, including one we authored,
have indicated the use of bisphosphonates as a successful
treatment of bone LCH (28). However, all of these case re-
ports lack the fundamental background for the rationale. Bis-
phosphonates appear to act when administered at therapeutic
doses only in bone, which is probably due to their specific
affinity to this tissue. This group of compounds is known to
have an inhibitory effect on the number and activation of os-
teoclasts (29). Thus, this study has provided a rationale for
the use of bisphosphonates in the treatment of LCH patients.
 
MATERIALS AND METHODS
 
Tissue samples.
 
Representative specimens of formalin-fixed, paraffin-
embedded tissue from 26 patients with a diagnosis of LCH were identified
by immunohistochemistry using S-100 and CD1a as markers. All biopsies
showed characteristic CD1a
 
 
 
 LC cells, CD68
 
 
 
 macrophages, CD3
 
 
 
 T cells,
and eosinophils. 15 specimens were obtained from bone in cases of ostotic
LCH, 7 were obtained from skin biopsies in cases of isolated skin disease,
and 4 were obtained from excisional lymph node biopsies from patients
with solitary lymph node involvement. MGCs were seen in 20 out of the
26 cases. One tissue each of Paget’s disease, dermatopathic lymphadenopa-
thy, and normal skin were used as methodological controls to avoid false
positive or negative stains due to technical flaws. Lesional tissue of Paget’s
disease of the bone, a disease characterized by the presence of activated os-
teoclasts, was used as positive control for the osteoclast-like MGCs of LCH
lesions. Dermatopathic lymphadenopathy, a disease characterized by the ac-
cumulation of CD1a
 
 
 
 DCs, but without MGCs and normal skin, was used
as negative control. Experiments were approved by the ethical committee
of Leiden University Medical Center.
 
Antibodies.
 
All staining was done in PBS with 1% BSA. Mouse monoclo-
nal antibodies to CD1a (1CA04), MMP-9 (4A3), and CD31 (JC/70A) were
obtained from Neomarkers. Goat and rabbit polyclonal antibodies to CatK,
M-CSF, and GM-CSF, respectively, were obtained from Santa Cruz Bio-
technology, Inc. The mouse monoclonal to RANKL (70525) and the goat
polyclonal to RANK were obtained from R&D Systems. The rabbit poly-
clonal to CD3 and the mouse monoclonal to Ki-67 (MIB-1) were obtained
from DakoCytomation. The mouse monoclonals to VNR (CJ00) and
ICAM-1 (23G12) were obtained from Novocastra. The mouse monoclonal
to CD68 (514H12) was obtained from Serotec. Secondary antibodies for
enzymatic staining were obtained from DakoCytomation, and substrate
chemicals were obtained from Vector Laboratories. Secondary immunoflu-
orescent reagents were goat anti–mouse, goat anti–rabbit, and donkey anti–
goat isotype-specific Alexa Fluor antibodies (Molecular Probes).
 
Immunohistochemistry.
 
The preparation of paraffin sections for staining
was performed as described previously (30). Double and triple stainings with
primary anticytokine, cytokine receptors, or osteoclast markers in combina-
tion with cell-specific markers were detected fluorescently using the rele-
vant secondary goat anti–mouse, goat anti–rabbit, or donkey anti–goat
isotype-specific Alexa Fluor 488, 647, or 546 secondary antibodies. Re-
placement of the primary antibodies by 1% PBS/BSA was used as a negative
control. Results were analyzed by confocal microscopy using a confocal mi-
croscope in fluorescence and brightfield mode (LSM 510; Carl Zeiss Micro-
Imaging, Inc.).
 
Single enzymatic staining for TRAP.
 
TRAP staining was performed
using a combination of solutions that include naphtol–AS BI phosphate,
dimethylformamide, tartaric acid, acetate buffer, vermoal buffer, sodium ni-
trite, and pararoseaniline. Tissue sections were deparaffinized, rehydrated,
and incubated with the reactive solution for 20 min. After washing with
distilled water, the tissue sections were counterstained with Mayer’s hema-
toxylin and mounted using Histomount media (National Diagnostics).
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